Incyte (LTS:0J9P) Additional Paid-In Capital : $5,070 Mil(As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Incyte Additional Paid-In Capital?

Incyte's quarterly additional paid-in capital increased from Sep. 2023 ($4,949 Mil) to Dec. 2023 ($5,016 Mil) and increased from Dec. 2023 ($5,016 Mil) to Mar. 2024 ($5,070 Mil).

Incyte's annual additional paid-in capital increased from Dec. 2021 ($4,567 Mil) to Dec. 2022 ($4,792 Mil) and increased from Dec. 2022 ($4,792 Mil) to Dec. 2023 ($5,016 Mil).

Incyte Additional Paid-In Capital Historical Data

The historical data trend for Incyte's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Additional Paid-In Capital Chart

Incyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

4,044.49

4,352.86

4,567.11

4,792.04

5,016.12

Incyte Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															4,856.91	4,925.63	4,949.02	5,016.12	5,070.29

Incyte Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Incyte Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Incyte's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Incyte (LTS:0J9P) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (LTS:0J9P) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

INCY:USA 1INCY:Italy ICY:Germany I1NC34:Brazil

Address

1801 Augustine Cut-Off, Wilmington, DE, USA, 19803

Website

https://www.incyte.com

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Incyte (LTS:0J9P) Headlines

No Headlines